CLINICAL TRIALS PROFILE FOR EVENAMIDE
✉ Email this page to a colleague
Clinical Trials for Evenamide
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03446274 ↗ | An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects | Unknown status | Newron Pharmaceuticals SPA | Phase 1 | This is a single-center, open-label, non-randomized, single dose of 14C-NW-3509 capsule study in 6 healthy male subjects. |
| NCT04461119 ↗ | Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia | Completed | Newron Pharmaceuticals SPA | Phase 2 | This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia. |
| NCT07184619 ↗ | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | NOT_YET_RECRUITING | Newron Pharmaceuticals SPA | PHASE3 | This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Evenamide
Condition Name
Clinical Trial Locations for Evenamide
Trials by Country
Clinical Trial Progress for Evenamide
Clinical Trial Phase
Clinical Trial Sponsors for Evenamide
Sponsor Name
